Law Offices of Frank R. Cruz Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”). Inovio investors have until April 7, 2026 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR INOVIO PHARMACEUTICALS, INC. (INO) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [e-mail], by telephone at [phone], or visit our website at www.frankcruzlaw.com.

What Happened?

On August 8, 2024, after market hours, Inovio released its second quarter 2024 financial results, revealing that it expected to submit the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (‘FDA”) for its recurrent respiratory papillomatosis “RPR”) treatment, INO-3107, in mid-2025, despite previous claims of a mid-2024 submission, due to a “manufacturing issue” with a component of the Company’s proprietary investigational medical device, CELLECTRA.

On this news, Inovio’s stock price fell $0.27, or 3.1%, to close at $8.44 per share on August 9, 2024, thereby injuring investors.

Then, on December 29, 2025, Inovio disclosed that the FDA had accepted the INO-3107 BLA on a standard review timeline rather than the accelerated review timeline that the Company touted the prospects of. The Company further stated that it did not plan to seek approval under the standard review timeline and planned to request a meeting with the FDA to discuss pursuing accelerated approval.

On this news, Inovio’s stock price fell $0.56, or 24.45%, to close at $1.73 per share on December 29, 2025, thereby injuring investors further.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) manufacturing for Inovio's CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Inovio securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: [phone]
Email: [e-mail]
Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.